The University of Southampton
University of Southampton Institutional Repository

Pharmacological targeting of PI3K isoforms as a therapeutic strategy in chronic lymphocytic leukaemia

Pharmacological targeting of PI3K isoforms as a therapeutic strategy in chronic lymphocytic leukaemia
Pharmacological targeting of PI3K isoforms as a therapeutic strategy in chronic lymphocytic leukaemia
PI3K? inhibitors such as idelalisib are providing improved therapeutic options for the treatment of chronic lymphocytic leukaemia (CLL). However under certain conditions, inhibition of a single PI3K isoform can be compensated by the other PI3K isoforms, therefore PI3K inhibitors which target multiple PI3K isoforms may provide greater efficacy. The development of compounds targeting multiple PI3K isoforms (?,?,?,?) in CLL cells, in vitro, resulted in sustained inhibition of BCR signalling but with enhanced cytotoxicity and the potential for improve clinical responses. This review summarises the progress of PI3K inhibitor development and describes the rationale and potential for targeting multiple PI3K isoforms.
2213-0489
60-63
Blunt, Matthew D.
b1109de3-6045-4bc3-bd77-6cf26504697d
Steele, Andrew J.
4349f6aa-2e3a-49a8-be73-7716056ae089
Blunt, Matthew D.
b1109de3-6045-4bc3-bd77-6cf26504697d
Steele, Andrew J.
4349f6aa-2e3a-49a8-be73-7716056ae089

Blunt, Matthew D. and Steele, Andrew J. (2015) Pharmacological targeting of PI3K isoforms as a therapeutic strategy in chronic lymphocytic leukaemia. Leukemia Research Reports, 4 (2), 60-63. (doi:10.1016/j.lrr.2015.09.001).

Record type: Article

Abstract

PI3K? inhibitors such as idelalisib are providing improved therapeutic options for the treatment of chronic lymphocytic leukaemia (CLL). However under certain conditions, inhibition of a single PI3K isoform can be compensated by the other PI3K isoforms, therefore PI3K inhibitors which target multiple PI3K isoforms may provide greater efficacy. The development of compounds targeting multiple PI3K isoforms (?,?,?,?) in CLL cells, in vitro, resulted in sustained inhibition of BCR signalling but with enhanced cytotoxicity and the potential for improve clinical responses. This review summarises the progress of PI3K inhibitor development and describes the rationale and potential for targeting multiple PI3K isoforms.

Text
__userfiles.soton.ac.uk_Library_SLAs_Work_for_ALL's_Work_for_ePrints_Accepted Manuscripts_Blunt_Pharmacological.pdf - Other
Download (811kB)
Other
1-s2.0-S2213048915300194-main.pdf__tid=252d5062-0248-11e6-8c30-00000aacb35e&acdnat=1460642136_7ebd11331ba273670568ec9fc39280c2 - Version of Record
Download (676kB)

More information

Accepted/In Press date: 11 September 2015
e-pub ahead of print date: 18 September 2015
Published date: 2015
Additional Information: CLL, PI3K, idelalisib, duvelisib
Organisations: Cancer Sciences

Identifiers

Local EPrints ID: 381796
URI: http://eprints.soton.ac.uk/id/eprint/381796
ISSN: 2213-0489
PURE UUID: 876d929f-7bd4-429d-910f-dca160923b66
ORCID for Andrew J. Steele: ORCID iD orcid.org/0000-0003-0667-1596

Catalogue record

Date deposited: 22 Sep 2015 16:06
Last modified: 20 Jul 2019 00:44

Export record

Altmetrics

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×